About Us

Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.

Dr. Kurt Gish has more than 25 years of experience in antibody-drug conjugates for oncology, starting with scientist positions at Affymetrix and Eos Biotechnology, followed by positions as Director of Biologics Technologies at PDL BioPharma, and Research Fellow at AbbVie. With his expertise in target discovery and therapeutics development, he has led two ADC products from concept into phase I human trials and is the inventor on 27 issued US patents. He earned his Ph.D. in Biology at Stanford University, followed by a post-doctoral fellowship in molecular immunology at the DNAX Research Institute (now Merck Research Laboratories). Kurt also serves on the Scientific Advisory Board of the Myeloma Investment Fund of the Multiple Myeloma Research Foundation.

Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data. 

Biochemistry PhD in structural biology, specializing in protein engineering. With experience as a protein scientist in drug discovery, I am passionate about understanding and manipulating protein structures to innovate therapeutics. Dedicated to scientific excellence, I aim to contribute to the development of transformative solutions in healthcare. Outside of the lab you can find me in the mountains chasing Colorado cutthroats.

Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.

Clara is a protein scientist coming from Watchmaker Genomics with 4+ years of experience in protein purification ranging from small scale prototyping to large scale manufacturing. She has additional experience in protein expression, characterization and DNA/RNA library preparation. Prior to her work in industry, Clara obtained her master’s degree from New Mexico State University where she studied Rho Family GTPases during oocyte meiosis using fluorescent biosensors and 3D live-cell microscopy.

Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.

Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.

Humza is a Systems Biologist with knowledge and expertise in cell biology, computational biology, quantitative and high throughput, fluorescence microscopy, live-cell imaging, flow cytometry, single-cell analysis, and cancer biology. During his graduate work at the University of Colorado Boulder, he studied single-cell fate variability in the proliferative responses of cancer cells to acute chemotherapy treatment. Humza is passionate about leveraging novel tools and methods to extract meaningful insights into complex biological processes.

Nicole has over 20 years of experience as an Office Manager and Human Resources professional with experience in event planning, team building, and employee workplace management and deep experience in startups. With a Masters degree in Organizational Leadership specializing in HR Management, she is highly organized, extremely personable and professional.

Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.

Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.